Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1876]

Costly drugs versus paclitaxel as first line therapy for locally advanced or...

Dr Hope Rugo - University of California San Francisco, USA

Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, USA )

EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2...

Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA

EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )

Trastuzumab emtansine improves progression-free survival for HER2-positive...

Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA

Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )

Recent developments in neoadjuvant therapy

Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany

Recent developments in neoadjuvant therapy ( Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany )

Highlights and goals of IMPAKT 2012

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )

PI3K and the heterogeneity of small tumour breast cancer

Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium

PI3K and the heterogeneity of small tumour breast cancer ( Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium )

Molecularly characterising triple negative breast cancer

Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium

Molecularly characterising triple negative breast cancer ( Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium )

Endocrine therapy and endocrine resistant breast cancer

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Endocrine therapy and endocrine resistant breast cancer ( Prof Mitch Dowsett – The Institute for Cancer Research, London, UK )

Neoadjuvant therapy and PCR through chemotherapy prior to surgery

Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium

Neoadjuvant therapy and PCR through chemotherapy prior to surgery ( Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium )

Minimising recurrence by using most effective treatment

Prof Fabrice Andre – Institut Gustave Roussy, Paris, France

Minimising recurrence by using most effective treatment ( Prof Fabrice Andre – Institut Gustave Roussy, Paris, France )

Overcoming drug resistance and targeting critical pathways

Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA

Overcoming drug resistance and targeting critical pathways ( Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA )

Heterogeneity of tumours and the challenges of biomarker development

Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy

Heterogeneity of tumours and the challenges of biomarker development ( Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy )

More from ecancer